The effects of empagliflozin, dietary energy restriction, or both on appetite‐regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The <scp>SEESAW</scp> randomized, double‐blind, placebo‐controlled trial-Reference-Cited by-同舟云学术

The effects of empagliflozin, dietary energy restriction, or both on appetite‐regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double‐blind, placebo‐controlled trial

Published:2022-05-13 Issue:8 Volume:24 Page:1509-1521
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Sargeant Jack A.¹²^ORCID,King James A.²³^ORCID,Yates Thomas¹²,Redman Emma L.¹²⁴,Bodicoat Danielle H.⁵,Chatterjee Sudesna⁶,Edwardson Charlotte L.¹²,Gray Laura J.⁷,Poulin Benoit¹²,Waheed Ghazala¹²^ORCID,Waller Helen L.¹²,Webb David R.¹²⁴^ORCID,Willis Scott A.²³,Wilding John P. H.⁸^ORCID,Khunti Kamlesh¹⁴⁹^ORCID,Stensel David J.²³¹⁰,Davies Melanie J.¹²⁴^ORCID

Affiliation:

1. Diabetes Research Centre University of Leicester Leicester UK

2. National Institute for Health Research (NIHR) Leicester Biomedical Research Centre Leicester UK

3. School of Sport, Exercise and Health Sciences Loughborough University Leicestershire UK

4. Leicester Diabetes Centre University Hospitals of Leicester NHS Trust Leicester UK

5. Simplified Data Leicester UK

6. Milton Keynes University Hospital Milton Keynes UK

7. Department of Health Sciences University of Leicester Leicester UK

8. Department of Cardiovascular and Metabolic Medicine University of Liverpool Liverpool UK

9. NIHR Applied Research Collaboration East Midlands Leicester UK

10. Faculty of Sport Sciences Waseda University Tokorozawa Japan

Funder

Boehringer Ingelheim

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14721

Reference41 articles.

1. Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus

2. Weight loss variability with SGLT2 inhibitors and GLP‐1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities

3. Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial

4. Mechanisms of weight regain.

5. Energy balance and metabolic changes with sodium‐glucose co‐transporter 2 inhibition;Rajeev SP;Diabetes Obes Metab.,2015

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Changes in daily intake of nutrients and foods including confectionery after the initiation of empagliflozin in Japanese patients with type 2 diabetes: a pilot study;BMC Nutrition;2024-07-04

2. The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials;Diabetes, Obesity and Metabolism;2024-04-11

3. Obesity and the kidney: mechanistic links and therapeutic advances;Nature Reviews Endocrinology;2024-02-13

4. No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double‐blind, placebo‐controlled, cross‐over trial (ENERGIZE);Diabetes, Obesity and Metabolism;2023-09-05

5. Association of Sodium-Glucose Cotransporter 2 Inhibitors with Osteomyelitis and Other Lower Limb Safety Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials;Journal of Clinical Medicine;2023-06-09